Research and surveillance must continue. The evidence base for policies and treatments has grown, but important questions remain: long-term effectiveness of newer pharmacotherapies in diverse populations, best ways to combine interventions across sectors, and mechanisms by which social determinants exert their effects. Ongoing monitoring of population weight trends and inequities can guide policy adjustments.